Evidence map›Paper›PMID 41718399›Full record

ArticleAntibodies (Basel, Switzerland)2026

Antibody Screening and Binding Prediction Analysis Targeting Stx2.

Jilei Wu, Chenghua Liu, Fenghao Peng, Zeyuan Yu, Chunxia Qiao, Guang Yang, Heng Luo, Keyi Sun, Ziyao Ning, Jing Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jilei WuCollege of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212000, China.
Chenghua LiuState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
Fenghao PengState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
Zeyuan YuSchool of Artificial Intelligence and Data Science, University of Science and Technology of China, Hefei 230026, China.
Chunxia QiaoState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
Guang YangState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
Heng LuoCollege of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212000, China.
Keyi SunCollege of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212000, China.
Ziyao NingSchool of Pharmacy, Qingdao University, Qingdao 266071, China.
Jing WangState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.ORCID 0000-0001-9413-2378
Yan WenCollege of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212000, China.
Jijun YuState Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.

Funding

Jiangsu University of Science and Technology Grant No. KYCX24_4148
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Escherichia coli O157:H7 infectionhuman monoclonal antibodyImmuneBuilderShiga toxin type 2 (Stx2)structural prediction

Identifiers

PMID41718399
PMCPMC12921925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.